Dr. David Guyer is the Co-founder, President, and CEO of EyeBio, and a Venture Partner at SV Health Investors. He is also the Co-founder and former CEO and Executive Chairman of Iveric Bio (formerly Ophthotech). Under his leadership, Iveric Bio entered a major partnership with Novartis and developed IZERVAY, the first complement inhibitor for dry macular degeneration, leading to Iveric’s $5.9B acquisition by Astellas in 2023.

Dr. Guyer has extensive experience in medical, drug development, and commercial aspects of ophthalmology. He has served on the boards of over 20 companies and co-founded three companies, two of which completed IPOs, with all three being successfully acquired. He also co-founded Eyetech Pharmaceuticals, where he developed the first anti-VEGF drug for retinal diseases and served as CEO until its acquisition by OSI Pharmaceuticals in 2005.

Previously, Dr. Guyer was a professor and Chairman of the Department of Ophthalmology at New York University School of Medicine. He holds a B.S. from Yale College and an M.D. from Johns Hopkins Medical School, completed his ophthalmology residency at Wilmer Ophthalmological Institute at Johns Hopkins Hospital, and a retinal fellowship at Massachusetts Eye and Ear Infirmary at Harvard Medical School.